| Size | Price | Stock | Qty |
|---|---|---|---|
| 500g |
|
||
| Other Sizes |
|
| ln Vitro |
Initial concentrations of enteric-derived uremic toxins (e.g., IAA) may rise to levels of 1 μg/mL or 10 μg/mL; however, sevelamer carbonate (15 mg/mL; pH=6 or 8) may prevent this rise [5].
|
|---|---|
| ln Vivo |
The polymer structure of sevelamer carbonate is identical to that of sevelamer hydrochloride, making it an anion exchange resin; however, carbonate ions are used in place of the anion [4]. Sevelamer hydrochloride and sevelamer carbonate both lower serum phosphorus levels and calcium-phosphorus products to a comparable degree. The body may experience less metabolic acidosis from sevelamer carbonate than from sevelamer hydrochloride, and it also significantly lowers LDL cholesterol levels [1]. Npt2b-deficient mice's blood phosphate levels are markedly lowered by sevelamer carbonate (oral; 1% mixed in meal; 2-3 weeks). Sevelamer carbonate therapy also helps to keep serum phosphate levels within normal limits, and Npt2b attenuates hyperphosphatemia in control mice [3]. Orally given at 1% mixed in meal for two to three weeks, sevelamer carbonate did not change serum phosphate levels in uremic WT mice (10.04 mg/dl, untreated vs. 9.67 mg/dl, treatment mg/dl); however, in a uremic mouse model, it further decreased serum phosphate levels in uremic Npt2b−/− mice [3].
|
| Animal Protocol |
Animal/Disease Models: WT and Npt2b−/− CKD mouse model [3]
Doses: 1% mixed in the diet Route of Administration: oral; 1% mixed in the diet; 2-3 weeks Experimental Results: Chronic hyperphosphatemia in mice alleviate. |
| References |
[1]. Mary M Barna, et al.Sevelamer carbonate.Ann Pharmacother. 2010 Jan;44(1):127-34.
[2]. Barbara Ruggiero, et al. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. Am J Kidney Dis [3]. Susan C Schiavi, et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol. 2012 Oct;23(10):1691-700. [4]. Yongsheng Yang, et al. Evaluation of the In Vitro Efficacy of Sevelamer Hydrochloride and Sevelamer Carbonate. J Pharm Sci. 2016 Feb;105(2):864-875 [5]. Bennis Y, et al. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Toxins (Basel). 2019 May 17;11(5):279. |
| Molecular Formula |
(C3H7N)M.(C3H5CLO)N.(CH2O3)X
|
|---|---|
| Molecular Weight |
0
|
| Exact Mass |
0
|
| CAS # |
845273-93-0
|
| Related CAS # |
Sevelamer hydrochloride;152751-57-0;Sevelamer;52757-95-6
|
| Appearance |
Solid powder
|
| SMILES |
C=CC[NH3+].OC([O-])=O.ClCC1CO1
|
| Chemical Name |
poly(allylamine-co-N,N'-diallyl-1,3diamino-2-hydroxypropane) carbonate salt
|
| Synonyms |
GT335-012; GT-335-012; GT 335-012; GT335012; GT-335012; GT 335012;Sevelamer carbonate; Renvela;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
